Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zalunfiban versus placebo in presumed STEMI in the pre-hospital setting
NL-OMON60280Phase 3Completed
- Sponsor
- CeleCor Therapeutics
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myocardial infarction (MI) comparing Zalunfiban with Placebo (2 arms). Primary endpoints: 30-day ranked clinical outcome and Severe or life-threatening bleeding. Started Apr 2021; status: completed.
02
Drugs
zalunfiban
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on NL-OMON60280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60280.